简体
简体中文
繁體中文

Nasus Pharma NSRX

等待开盘 09-02 09:30:00 美东时间

3.825

-0.259

-6.34%

华盛通华盛通
立即下载
  • 最 高4.08
  • 今 开3.85
  • 成交量 1.57万股
  • 最 低 3.43
  • 昨 收 4.084
  • 总市值 4479.38万
  • 52周最高 9.50
  • 市盈率 --
  • 换手率 0.13%
  • 52周最低 1.98
  • 委 比 0.00%
  • 总股本 1171.08万
  • 历史最高 9.9899
  • 量 比 1.83
  • 振 幅 15.92%
  • 历史最低 1.98
  • 每 手 1
  • 风险率 2.09%

个股概要

财务分析

公司资料

相关新闻

分红派息

  • 分时图
  • 日k
  • 周k
  • 月k

相关新闻

更多
  • Nasus Pharma CFO Eyal Rubin to leave

    Nasus Pharma (NSRX) on Wednesday said Chief Financial Officer, Eyal Rubin will be leaving the company to pursue a new opportunity outside the life science industry.  Rubin will remain with Nasus throu...

    08-19 19:05

  • Nasus Pharma Announces Transition of Chief Financial Officer

    Nasus Pharma Ltd. announced that Chief Financial Officer Eyal Rubin will leave the company to pursue a new opportunity outside the life sciences industry. Rubin will remain with the company until September 18, 2026, to ensure a smooth transition. Oren Elmaliach, Director of Finance, has been appointed Interim CFO. Elmaliach has been with Nasus since its inception and has over 15 years of financial experience, including working with public and pri...

    08-19 11:00

  • Nasus Pharma 1H non-GAAP EPS of -$0.54

    Nasus Pharma Ltd. press release (NSRX): 1H Non-GAAP EPS of -$0.54. Six months ended June 30, 2026, net loss totaled $5.94M. Research and development expenses increased to $2.59M while general and admi...

    08-17 22:57

  • Nasus Pharma H1 EPS $(0.54) Misses $(0.20) Estimate

    Nasus Pharma (AMEX:NSRX) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.20) by 170 percent. This is a 217.65 percent decrease over losses of $(0.17) per share from the same period last year.

    08-17 20:15

  • Nasus Pharma Appoints Brendan O'Grady As CEO, Succeeding Dan Teleman, Effective July 27

    Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus", "Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced the appointment of pharma industry veteran Brendan P. O'Grady as its Chief Executive Officer. Mr. O'Grady wi...

    07-28 19:33

  • Nasus Pharma to Participate in the Zacks Life Sciences Investor Forum

    Nasus Pharma Ltd. announced that its management will present at the Zacks Life Sciences Investor Forum on June 24-25, 2026. The virtual event will feature live, interactive sessions where investors can submit questions to management. Nasus Pharma, a clinical-stage company, is developing innovative intranasal powder products for acute medical conditions. Its NS002 product is a needle-free epinephrine option for anaphylaxis patients. The company’s ...

    06-22 12:00

  • Nasus Pharma Announces NS003 Trial Demonstrates Preclinical Pharmacokinetic Profile Comparable To IV

    Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced positive results from a

    06-09 20:02

  • Nasus Pharma Announces Positive Results from Preclinical Pharmacokinetic and Safety Study of Intranasal Ondansetron (NS003) 

    Nasus Pharma announced positive preclinical results for NS003, its intranasal powder formulation of ondansetron, showing comparable pharmacokinetics and safety to IV ondansetron in animal studies. The company plans to initiate a first-in-human PK study in Q3 2026, targeting unmet needs in chemotherapy and post-operative nausea and vomiting.

    06-09 12:00

  • Nasus Pharma to Host Virtual KOL Event on June 10, 2026 to Discuss NS002 for the Treatment of Anaphylaxis

    Nasus Pharma will host a virtual KOL event on June 10, 2026, featuring Michael S. Blaiss, MD, and Joel Brooks, DO, MPH, to discuss anaphylaxis treatment needs. The event will highlight NS002, the company's epinephrine intranasal powder candidate, which shows faster absorption than EpiPen®. NS002 aims to provide a needle-free alternative for anaphylaxis treatment, addressing challenges faced by pediatric patients. The event includes a Q&A session ...

    06-01 12:00

  • 美股夜盘 | 课标科技涨55.26%,Real Messenger Corporation Class A涨25.03%

    Replimune涨-62.61%;Nasus Pharma Ltd.涨-15.91%;雷亚电子涨-15.87%

    04-13 08:10